Since March 2019, E-cigarette or Vaping product associated lung injury (EVALI) has become an ongoing epidemic with more 2600 cases reported in the span of a few months in the United States. EVALI is defined as acute lung injury that develops secondary to the use of e-cigarettes or vaping products within the previous 90 days after exlusion of other possible inciting factors. Vitamin E acetate is believed to play a significant role in its pathogenesis. Treatment involves use of corticosteroids and further avoidance of these products. We describe a case series of 8 patients with EVALI, their clinical course and outcomes. All patients showed an excellent response to corticosteroids. In our experience, prognosis of EVALI is excellent, with complete resolution of symptoms in patients who followed up at 8 weeks.

自2019年3月以来，电子烟或Vaping产品相关的肺损伤（EVALI）成为一种持续流行的疾病，在几个月的时间内，美国报告了2600多例病例。EVALI被定义为急性肺损伤，在排除其他可能的诱因后的90天内，由于使用电子烟或电子烟产品而继发发展。据信维生素E乙酸盐在其发病机理中起重要作用。治疗包括使用皮质类固醇和进一步避免使用这些产品。我们描述了8例EVALI患者的病例系列，他们的临床过程和结果。所有患者均显示对皮质类固醇的优良反应。根据我们的经验，EVALI的预后非常好，随访8周的患者症状可以完全缓解。